O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

British Journal of Cancer

Volumn 100, Issue 8, 2009, Pages 1250-1256

  Watson, A J ^a   Middleton, M R ^b   McGown, G ^a   Thorncroft, M ^a   Ranson, M ^c   Hersey, P ^d   McArthur, G ^e   Davis, I D ^f   Thomson, D ^g   Beith, J ^h   Haydon, A ⁱ   Kefford, R ^j   Lorigan, P ^c   Mortimer, P ^k   Sabharwal, A ^b   Hayward, O ^b   Margison, G P ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d Newcastle Melanoma Unit   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f AUSTIN HEALTH   (Australia)

^g PRINCESS ALEXANDRA HOSPITAL   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ ALFRED HOSPITAL   (Australia)

^j WESTMEAD HOSPITAL   (Australia)

^k KuDOS Pharmaceuticals   (United Kingdom)

more..

Author keywords

Lomeguatrib; Melanoma; O6 methylguanine DNA methyltransferase; Temozolomide

Indexed keywords

7 METHYLGUANINE; DNA; LOMEGUATRIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ARTICLE; CELL ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DRUG DOSE REDUCTION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; BIOPSY; DACARBAZINE; DISEASE PROGRESSION; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA, NEOPLASM; HUMANS; KINETICS; MELANOMA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PURINES;

EID: 64949162740     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605015     Document Type: Article

References (32)

1. Begg AC (2002) Oxford Textbook of Oncology 2nd edn, Vol 1. Oxford University Press: Oxford, pp 75-87
2. Brennand J, Margison GP (1986) Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harbouring the Escherichia coli alkyltransferase gene. Proc Natl Acad Sci USA 83: 6292-6296
3. 6-methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis 13: 1503-1507
4. 6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung and ovary. Cancer Res 54: 4131-4134
5. Clemons M, Ranson M, Margison JM, El Teraifi H, Griffiths A, Kelly J, Morris CQ, Howell A, Margison GP (2003) Pharmacokinetic, biochemical and clinical effects of a DTIC - BCNU combination therapy in patients with advanced breast cancer. Int J Cancer 103: 686-692
6. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87: 5368-5372
7. 6-methylguanine-DNA methyltransferase in human melanoma metastases. Eur J Cancer 33: 129-134
8. 6-benzylguanine. Biochem J 298: 231-235
9. Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, Bizzari JP (1994) Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine in patients with melanoma. Eur J Cancer 29A: 711-719
10. 6-methylguanine in templates for RNA polymerase. Biochim Biophys Acta 308: 310-316
11. 6- methylguanine. Biochem Pharmacol 43: 1101-1107
12. 6-alkylguanine- DNA alkyltransfer-ase activity in human myeloid cells. J Clin Invest 76: 2106-2114
13. Harrison KL, Wood M, Lees NP, Hall N, Margison GP, Povey AC (2001) Development and application of a sensitive and rapid immunoassay for the quantitation of N7-methyldeoxyguanosine in DNA samples. Chem Res Toxicol 14:295-301
14. 6- methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat Res 381: 227-241
15. Karran P, Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833-839
16. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, van den Oord JJ, Spatz A, Sarasin A (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27: 565-573
17. 6-methylguanine and 3-methyladenine. Chem Biol Interact 57: 107-121
18. Lee SM, Margison GP, Woodcock AA, Thatcher N (1993) Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 67: 1356-1360
19. 6-Alkylguanine-DNA alkyltransferase expression in Human brain tumours: possible therapeutic significance. Carcinogenesis 17: 637-641
20. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69: 452-456
21. Lips J, Kaina B (2001) Repair of O(6)-methylguanine is not affected by thymine base pairing and the presence of MMR proteins. Mutat Res 487: 59-66
22. 6-(4-bromothenyl) guanine improves the therapeutic index of TMZ against A375M melanoma xenografts. Int J Cancer 85: 248-252
23. 6-methylguanine formation repair protein depletion clinical outcome with a 4 h schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 88(3): 469-473
24. Middleton MR, Margison GP (2003) Enhancing chemotherapy by inactivation of a DNA repair pathway. Lancet Oncol 4: 37-44
25. Naumann SC, Roos WP, Jöst E, Belohlavek C, Lennerz V, Schmidt CW, Christmann M, Kaina B (2009) Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 100: 322-333
26. Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR (2007) Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 25: 2540-2545
27. 6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic and phamacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 12: 1577-1584
28. Rew DA, Wilson GD (2000) Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J Surg Oncol 26: 405-417
29. Schold Jr SC, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence M, Fulton D, Fink KL, Prados MD (2000) A phase I trial of 1,3-bis (2-chloroethyl)-1-nitrosourea plus TMZ: a North American Brain Tumor Consortium study. Neuro-oncol 2: 34-39
30. 6-alkylguanine-DNA-alkytransferaes. Clin Cancer Res 2: 1129-1134
31. 6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 152: 49-61
32. Yan L, Bulgar A, Miao Y, Mahajan V, Donze JR, Gerson SL, Liu L (2007) Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha. Clin Cancer Res 13: 1532-1539